Copy to clipboard 
Medacta reported 1H21 orthopedic revenue of €177.5 million (USD $216.6 million), +31.7% vs. 1H20. The company’s performance remains impressive even against its 1H19 comparison, as it grew +17.1% compared to that period. Medacta pointed to growth drivers including the faster-than-expected recovery of surgical volumes, continued innovation with more than 50 new products registered and new customer acquisition through an expanded salesforce.
In June 2021, the company completed the first surgeries for its NextAR Augmented Reality Surgical Platform following the CE-Marking of its knee, shoulder and spine applications. This follows the May 2021 FDA clearance for the NextAR shoulder application in the U.S., where the knee application was cleared in 2020. Medacta expects that the system’s limited upfront capital investment and lean footprint (joint replacement and spine in a single platform) will appeal to ASCs.
Based on its first-half performance, Medacta increased its 2021 outlook to the range of $409 million to $458 million, representing growth between +10.7% and +24%.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $195.9 | $148.9 | $46.9 | 31.5% |
| Knees | $77.3 | $57.8 | $19.6 | 33.9% |
| Hips | $107.8 | $84.0 | $23.8 | 28.4% |
| Extremities | $10.7 | $7.2 | $3.5 | 49% |
| Spine | $20.3 | $15.3 | $5.0 | 32.5% |
| Sports Medicine | $0.4 | $0.2 | $0.2 | 84.8% |
| Total | $216.6 | $164.5 | $52.1 | 31.7% |
Geographic Sales
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $64.1 | $48.4 | $15.7 | 32.5% |
| OUS | $152.4 | $116.1 | $36.4 | 31.3% |
| EMEA | $93.0 | $72.3 | $20.7 | 28.6% |
| APAC | $52.5 | $38.9 | $13.6 | 35% |
| ROW | $7.0 | $4.9 | $2.1 | 42.6% |
| Total | $216.6 | $164.5 | $52.1 | 31.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medacta reported 1H21 orthopedic revenue of €177.5 million (USD $216.6 million), +31.7% vs. 1H20. The company's performance remains impressive even against its 1H19 comparison, as it grew +17.1% compared to that period. Medacta pointed to growth drivers including the faster-than-expected recovery of surgical volumes, continued innovation with...
Medacta reported 1H21 orthopedic revenue of €177.5 million (USD $216.6 million), +31.7% vs. 1H20. The company’s performance remains impressive even against its 1H19 comparison, as it grew +17.1% compared to that period. Medacta pointed to growth drivers including the faster-than-expected recovery of surgical volumes, continued innovation with more than 50 new products registered and new customer acquisition through an expanded salesforce.
In June 2021, the company completed the first surgeries for its NextAR Augmented Reality Surgical Platform following the CE-Marking of its knee, shoulder and spine applications. This follows the May 2021 FDA clearance for the NextAR shoulder application in the U.S., where the knee application was cleared in 2020. Medacta expects that the system’s limited upfront capital investment and lean footprint (joint replacement and spine in a single platform) will appeal to ASCs.
Based on its first-half performance, Medacta increased its 2021 outlook to the range of $409 million to $458 million, representing growth between +10.7% and +24%.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $195.9 | $148.9 | $46.9 | 31.5% |
| Knees | $77.3 | $57.8 | $19.6 | 33.9% |
| Hips | $107.8 | $84.0 | $23.8 | 28.4% |
| Extremities | $10.7 | $7.2 | $3.5 | 49% |
| Spine | $20.3 | $15.3 | $5.0 | 32.5% |
| Sports Medicine | $0.4 | $0.2 | $0.2 | 84.8% |
| Total | $216.6 | $164.5 | $52.1 | 31.7% |
Geographic Sales
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $64.1 | $48.4 | $15.7 | 32.5% |
| OUS | $152.4 | $116.1 | $36.4 | 31.3% |
| EMEA | $93.0 | $72.3 | $20.7 | 28.6% |
| APAC | $52.5 | $38.9 | $13.6 | 35% |
| ROW | $7.0 | $4.9 | $2.1 | 42.6% |
| Total | $216.6 | $164.5 | $52.1 | 31.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
